Medications That Cause Hyperkalemia
The most common drug-related causes of hyperkalemia are ACE inhibitors, ARBs, aldosterone antagonists (spironolactone/eplerenone), potassium-sparing diuretics, and trimethoprim-containing antibiotics, with risk dramatically increased in patients with renal impairment (GFR <45 mL/min) or when these agents are combined. 1, 2
Primary Medications That Decrease Potassium Excretion
RAAS Inhibitors (Highest Risk Category)
ACE inhibitors (lisinopril, enalapril, captopril, ramipril) cause hyperkalemia by blocking aldosterone production and impairing renal potassium excretion, with up to 10% of patients experiencing at least mild hyperkalemia 3, 4, 5
ARBs (losartan, valsartan, candesartan, olmesartan) carry equivalent hyperkalemia risk to ACE inhibitors through the same mechanism of aldosterone suppression 3, 2, 6
Direct renin inhibitors (aliskiren) should never be combined with ACE inhibitors or ARBs due to excessive hyperkalemia risk, particularly in patients with chronic kidney disease 3, 2
Sacubitril/valsartan (neprilysin inhibitor combined with ARB) increases hyperkalemia risk and requires the same monitoring as other RAAS inhibitors 2
Aldosterone Antagonists (Extreme Risk, Especially in Combination)
Spironolactone and eplerenone cause hyperkalemia in 2-5% of clinical trial patients but up to 24-36% in real-world practice, with risk increasing progressively when serum creatinine exceeds 1.6 mg/dL 1, 7, 8
The combination of spironolactone with ACE inhibitors or ARBs is particularly dangerous, with mean admission potassium of 7.7 mmol/L, requiring hemodialysis in 68% of cases and ICU admission in 48% 9
Spironolactone doses should not exceed 25 mg daily when combined with RAAS inhibitors, and should be initiated at 12.5 mg in patients with marginal renal function (GFR 30-49 mL/min) 1, 9
Triple combination of ACE inhibitor + ARB + aldosterone antagonist should be avoided entirely 1
Potassium-Sparing Diuretics
- Amiloride and triamterene directly block potassium excretion in the collecting duct and carry significant hyperkalemia risk, especially when combined with RAAS inhibitors 3, 2
Antimicrobials
Trimethoprim-sulfamethoxazole impairs renal potassium excretion and causes dose-related hyperkalemia, with particularly high risk in AIDS patients, those with renal insufficiency, and when combined with RAAS inhibitors 10, 11
Pentamidine similarly impairs potassium excretion through direct tubular effects 11
High-dose penicillin G can cause hyperkalemia when administered in large quantities 2
Immunosuppressants
- Calcineurin inhibitors (cyclosporine, tacrolimus) cause hyperkalemia by impairing renal potassium secretion through direct tubular effects 2, 11
Anticoagulants
- Heparin and low-molecular-weight heparins suppress aldosterone synthesis, leading to impaired potassium excretion 2, 11
Medications That Cause Transcellular Potassium Shift
Beta-blockers (particularly non-selective agents) can shift potassium out of cells, though this is rarely clinically significant as monotherapy 11
Succinylcholine causes acute potassium release from muscle cells and can precipitate life-threatening hyperkalemia in susceptible patients 11
Digitalis toxicity impairs Na-K-ATPase function, causing potassium shift out of cells 2
Mannitol can cause hyperkalemia through hyperosmolar-induced transcellular shift 2, 11
Medications That Increase Potassium Load
Potassium supplements and salt substitutes (commonly used in DASH diet) directly increase potassium intake and should be discontinued when initiating aldosterone antagonists 1, 2
Stored blood products contain high potassium concentrations due to red cell lysis during storage 2
Amino acids (aminocaproic acid, arginine, lysine) can increase potassium load when administered in high doses 2
Critical Risk Factors That Amplify Medication-Induced Hyperkalemia
Renal insufficiency is the single most important risk factor, with GFR <45 mL/min conferring 2.47-fold increased risk of severe hyperkalemia when using RAAS inhibitors or aldosterone antagonists 2
Diabetes mellitus increases risk through hyporeninemic hypoaldosteronism 9
Advanced age (>70 years) independently predicts progression to severe hyperkalemia once mild hyperkalemia develops 5
Acute kidney injury from dehydration or worsening heart failure dramatically increases risk 9
Congestive heart failure is independently associated with hyperkalemia during ACE inhibitor therapy 5
Monitoring and Prevention Strategies
Check potassium and creatinine within 2-3 days, again at 7 days, then monthly for 3 months after initiating or increasing doses of RAAS inhibitors or aldosterone antagonists 1
Discontinue or reduce potassium supplements when starting aldosterone antagonists 1, 7
Avoid NSAIDs and COX-2 inhibitors in patients on RAAS inhibitors, as they further impair renal potassium excretion 7
Consider adding loop or thiazide diuretics to promote potassium excretion when using RAAS inhibitors in high-risk patients 2, 6
Aldosterone antagonists should not be initiated when baseline potassium exceeds 5.0 mEq/L or creatinine exceeds 2.5 mg/dL in men or 2.0 mg/dL in women (GFR <30 mL/min) 1, 7
Instruct patients to stop aldosterone antagonists during episodes of diarrhea or dehydration 1
Management When Hyperkalemia Develops
Potassium >5.5 mEq/L should trigger discontinuation or dose reduction of the offending agent unless other reversible causes are identified 1
For patients requiring continued RAAS inhibition, consider switching from aldosterone antagonist to increased loop diuretic dosing 2
In patients with heart failure requiring aldosterone antagonists, ensure adequate diuretic coverage to promote kaliuresis 2